Terizidone is a second-line anti-TB drug of the oxazolidinone group, structurally related to linezolid. It is used in MDR/XDR-TB regimens.
Also known as: Terizidone
Terizidone and linezolid are both oxazolidinones with identical mechanism. Coadministration offers no additive benefit and increases toxicity.
Terizidone and linezolid are both oxazolidinones that act on the 50S ribosomal subunit, inhibiting protein synthesis initiation. There is no synergy between oxazolidinones — only duplication of side effects. Linezolid is known to cause peripheral neuropathy (with use >2 weeks), myelosuppression (thrombocytopenia) and lactic acidosis. Terizidone, being structurally similar, shares these risks. Coadministration does not increase efficacy but potentiates toxicity. In practice, only one oxazolidinone is chosen for the regimen.
Terizidone + linezolid: both oxazolidinones — toxicity duplication without benefit. Do not coadminister.
Both act on the 50S ribosomal subunit. No synergy — only duplication of side effects (neuropathy, myelosuppression).
Blood count, neurological symptoms.
Severe neuropathy, myelosuppression.
DO NOT coadminister. Choose only one oxazolidinone.
EMC-UK (MHRA) — approved Terizidone SmPC: https://www.medicines.org.uk/emc/product/8044/smpc ; DailyMed/FDA (NIH/NLM) — approved Linezolid label: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01415799-3799-4cd8-a04d-b4a196f6e2fa
No documented food or drink interactions.
No documented disease interactions.
No documented pregnancy or breastfeeding information.
Clinical and educational support tool. The information does not replace a medical prescription or the opinion of a qualified healthcare professional.
Terizidone is an oxazolidinone with tuberculostatic activity, structurally related to linezolid. It acts by binding to the 50S ribosomal subunit, inhibiting initiation of protein synthesis.
Binds to 23S RNA of the 50S ribosomal subunit, preventing formation of the 70S initiation complex — same mechanism as linezolid.
Oral bioavailability: high. Tmax: 1-2 hours.
Hepatically metabolised (CYP3A4). Shorter half-life than linezolid.
3-5 hours. Elimination: urine and faeces (metabolites).
Medicines from the same therapeutic group (ATC classification) or the same pharmacological class.
